IMW 2021 | MRD in myeloma
Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, talks on the role of measurable residual disease (MRD) in the management of patients with multiple myeloma and how MRD can be incorporated into clinical practice. Dr Usmani also talks on the future role of MRD, commenting on the potential use of MRD-driven adaptive strategies in the future. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.
